Jan Kolcava1,2, Monika Hulova1,2, Lucie Rihova3, Josef Bednarik1,2, Pavel Stourac4,5. 1. Faculty of Medicine, Masaryk University, Brno, Czech Republic. 2. Department of Neurology, University Hospital Brno, Jihlavská 340/20, 625 00, Brno, Czech Republic. 3. Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic. 4. Faculty of Medicine, Masaryk University, Brno, Czech Republic. Stourac.Pavel@fnbrno.cz. 5. Department of Neurology, University Hospital Brno, Jihlavská 340/20, 625 00, Brno, Czech Republic. Stourac.Pavel@fnbrno.cz.
Abstract
BACKGROUND: Natalizumab is an effective therapy in the treatment of relapsing-remitting multiple sclerosis; it induces lymphocytosis (NIL, natalizumab-induced lymphocytosis) and changes the peripheral lymphocyte pattern. METHODS: This study aims to evaluate NIL, peripheral blood lymphocyte subsets, CD4/CD8 ratio, and their impacts on JCV index and clinical data-No Evidence of Disease Activity (NEDA-3) and annualized relapse rate (ARR) in patients treated with natalizumab. RESULTS: Forty-one patients (33 women) were included in the study. The mean duration of follow-up on natalizumab treatment was 6.7 ± 3.2 years. Significant increases in relative lymphocytosis after 1 month, with a median of 40.4% (- 34.1 to + 145.5%) (p < 0.001), and after 1 year (49.0% (- 9.3 to + 127.6%)) (p < 0.001) were found. Significant differences were found after 1 month when comparing NIL between patients JCV-seroconverting (20.6% (- 17.7 to 72.7%)) and stable JCV-seronegative ones (43.5% (- 6.3 to +96.3%)) (p = 0.04). No significant difference NIL level was found between the patients exhibiting NEDA-3 status and those without it. ARR on natalizumab treatment correlated with CD4/CD8 ratio (r = 0.356; p = 0.021); patients who maintained NEDA-3 status over the whole treatment period exhibited a lower CD4/CD8 ratio (1.89 ± 1.08 vs. 2.5 ± 0.73; p < 0.04). CONCLUSION: This contribution reports the CD4/CD8 ratio as a possible biomarker for better clinical efficacy of natalizumab in patients exhibiting a lower CD4/CD8 ratio. NIL did not correlate with long-term therapeutic efficacy in patients treated with natalizumab, but was demonstrated as lower in patients JCV-seroconverting in the course of follow-up.
BACKGROUND:Natalizumab is an effective therapy in the treatment of relapsing-remitting multiple sclerosis; it induces lymphocytosis (NIL, natalizumab-induced lymphocytosis) and changes the peripheral lymphocyte pattern. METHODS: This study aims to evaluate NIL, peripheral blood lymphocyte subsets, CD4/CD8 ratio, and their impacts on JCV index and clinical data-No Evidence of Disease Activity (NEDA-3) and annualized relapse rate (ARR) in patients treated with natalizumab. RESULTS: Forty-one patients (33 women) were included in the study. The mean duration of follow-up on natalizumab treatment was 6.7 ± 3.2 years. Significant increases in relative lymphocytosis after 1 month, with a median of 40.4% (- 34.1 to + 145.5%) (p < 0.001), and after 1 year (49.0% (- 9.3 to + 127.6%)) (p < 0.001) were found. Significant differences were found after 1 month when comparing NIL between patients JCV-seroconverting (20.6% (- 17.7 to 72.7%)) and stable JCV-seronegative ones (43.5% (- 6.3 to +96.3%)) (p = 0.04). No significant difference NIL level was found between the patients exhibiting NEDA-3 status and those without it. ARR on natalizumab treatment correlated with CD4/CD8 ratio (r = 0.356; p = 0.021); patients who maintained NEDA-3 status over the whole treatment period exhibited a lower CD4/CD8 ratio (1.89 ± 1.08 vs. 2.5 ± 0.73; p < 0.04). CONCLUSION: This contribution reports the CD4/CD8 ratio as a possible biomarker for better clinical efficacy of natalizumab in patients exhibiting a lower CD4/CD8 ratio. NIL did not correlate with long-term therapeutic efficacy in patients treated with natalizumab, but was demonstrated as lower in patients JCV-seroconverting in the course of follow-up.
Entities:
Keywords:
Flow cytometry; JC virus; Multiple sclerosis; Natalizumab; T lymphocytes
Authors: Gary Bloomgren; Sandra Richman; Christophe Hotermans; Meena Subramanyam; Susan Goelz; Amy Natarajan; Sophia Lee; Tatiana Plavina; James V Scanlon; Alfred Sandrock; Carmen Bozic Journal: N Engl J Med Date: 2012-05-17 Impact factor: 91.245
Authors: Leonid Gorelik; Michaela Lerner; Sarah Bixler; Mary Crossman; Brian Schlain; Kenneth Simon; Amy Pace; Anne Cheung; Ling Ling Chen; Melissa Berman; Fairuz Zein; Ewa Wilson; Ted Yednock; Alfred Sandrock; Susan E Goelz; Meena Subramanyam Journal: Ann Neurol Date: 2010-09 Impact factor: 10.422
Authors: Michael W Ferenczy; Leslie J Marshall; Christian D S Nelson; Walter J Atwood; Avindra Nath; Kamel Khalili; Eugene O Major Journal: Clin Microbiol Rev Date: 2012-07 Impact factor: 26.132
Authors: Yolanda Aladro; Rodrigo Terrero; Marta Cerezo; Ricardo Ginestal; Lucía Ayuso; Virginia Meca-Lallana; Jorge Millán; Laura Borrego; Marisa Martinez-Ginés; Luisa Rubio; Clara de Andrés; Ambrosio Miralles; Cristina Guijarro; Elena Rodríguez-García; José Manuel García-Dominguez; Carmen Muñoz-Fernández; Carlos López de Silanes; Mayra Gómez; Israel Thuissard; María Cerdán; Itziar Palmí; Luis Felipe Díaz-Garzón; Jose Meca-Lallana Journal: J Neurol Sci Date: 2016-04-02 Impact factor: 3.181
Authors: Tae Kon Kim; Matthew J Billard; Eric D Wieder; Bradley W McIntyre; Krishna V Komanduri Journal: Hum Immunol Date: 2010-01 Impact factor: 2.850
Authors: C McGuigan; M Craner; J Guadagno; R Kapoor; G Mazibrada; P Molyneux; R Nicholas; J Palace; O R Pearson; D Rog; C A Young Journal: J Neurol Neurosurg Psychiatry Date: 2015-10-22 Impact factor: 10.154